Rubicon Research Limited vs Onesource Specialty Pharma Limited
An objective side-by-side of RUBICON and ONESOURCE, both in Pharmaceuticals: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-06 close
Latest results: RUBICON Sep 2026 · ONESOURCE Sep 2026
At a glance
- Rubicon Research Limited is the larger company by market value, about 1.5 times the size of Onesource Specialty Pharma Limited.
- Rubicon Research Limited earns the higher return on equity (22.9% against -0.0%).
- Over the past year the share prices returned +168.4% (RUBICON) and -13.7% (ONESOURCE).
| Metric | Rubicon Research RUBICON |
Onesource Specialty ONESOURCE |
|---|---|---|
| Size and price | ||
| Market cap | ₹27,468 Cr | ₹18,346 Cr |
| Share price | ₹1,659.30 | ₹1,599.80 |
| Valuation | ||
| P/E | 84.52 | — |
| P/B | 19.39 | 3.10 |
| EV/EBITDA | 55.90 | 50.82 |
| Dividend yield | — | 0.0% |
| Profitability | ||
| ROE | 22.9% | -0.0% |
| ROCE | — | 1.0% |
| Operating margin | 23.8% | 23.5% |
| Sales (TTM) | ₹2,100 Cr | ₹1,684 Cr |
| Net profit (TTM) | ₹325 Cr | ₹-2 Cr |
| Growth | ||
| Latest quarter sales YoY | +39.9% | +37.3% |
| Latest quarter profit YoY | +67.9% | +474.8% |
| Sales CAGR 3Y | — | +232.0% |
| Profit CAGR 3Y | — | +24.0% |
| Sales CAGR 5Y | — | +131.0% |
| Profit CAGR 5Y | — | +8.0% |
| Financial strength | ||
| Debt/Equity | 0.35 | 0.30 |
| Interest cover | 8.41 | 0.19 |
| Ownership | ||
| Promoter holding | 51.2% | 30.5% |
| Promoter change (4 qtrs) | — | +0.70 pp |
| Price performance | ||
| Return 1M | +5.31% | +4.66% |
| Return 3M | +8.21% | +2.74% |
| Return 1Y | +168.43% | -13.72% |
| Return YTD | +143.75% | -11.64% |
| Technical condition | ||
| Technical score | 75 | 70 |
| RS rating (1-99) | 97.00 | 68.00 |
| % vs 200-DMA | +35.17% | +3.18% |
| RSI (14) | 56.10 | 61.99 |
| % from 52-week high | -12.62% | -16.89% |
